Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.

Frequent consumption of a common drug that acts on the nervous system and treats a range of ailments may lead to faster ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris, ...

A grant from the Melissa Andrews Trust has funded a software update for the Pulmonary Function Test machine (PFT) at ...